Browsing Tag

STS101

Satsuma Pharmaceuticals and SNBL Announce Three Abstracts on STS101 for the Acute…

Eli Pacheco Jun 15, 2023 0

DURHAM, N.C., June 15, 2023 (GLOBE NEWSWIRE) -- Satsuma Pharmaceuticals, Inc., a late-stage biopharmaceutical company currently seeking regulatory approval from the U.S. Food and Drug…

Health

Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update

Eli Pacheco Dec 21, 2022 0

Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows differentiating robust and sustained antimigraine…

Health

Satsuma Pharmaceuticals Announces Positive Pharmacokinetic, Tolerability and Safety…

Eli Pacheco Jun 17, 2021 0

- All three dose strengths of STS101, administered with improved 2nd-generation nasal delivery device were well-tolerated and achieved target pharmacokinetic profile - - Initiating SUMMIT…